Background
This study aimed to compare the infection rate and infection‐related mortality among all renal replacement therapies during the COVID‐19 pandemics.
Methods
One thousand three hundred thirty‐six end‐stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID‐19 infection and mortality rates were compared between patient groups.
Results
The COVID‐19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID‐19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID‐19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (
p
< 0.001).
Conclusion
The COVID‐19 infection rate and mortality were significantly lower than those of CHD in all home‐based modalities subgroups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.